Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-04
2007-09-04
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S374000, C514S396000, C548S146000, C548S215000, C548S300100
Reexamination Certificate
active
10775980
ABSTRACT:
Compounds having the general structureand compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.
REFERENCES:
patent: 5693594 (1997-12-01), Niedermann et al.
patent: 6596746 (2003-07-01), Das et al.
patent: 2002/0161019 (2002-10-01), Dubowchik et al.
patent: 2004/0220233 (2004-11-01), Hynes et al.
patent: 2005/0130970 (2005-06-01), Miller et al.
patent: 1 256 578 (2002-11-01), None
patent: WO 03/004467 (2003-01-01), None
patent: WO 03/072557 (2003-09-01), None
Sycheva et al. “Compounds with potential antitubercular . . . ” CA 58:53202 (1963).
Tashika et al. “2-2-substituted-4-thiazolyl . . . ” CA 66:65472 (1967).
Hayakawa et al. “Preparation of aminoazoles . . . ” CA 139:364922 (2003).
Tashika et al. “2-(2-substituted-4-thiazolyl—benzimidazole derivatives” CA 66:65472 (1967).
JP 41 020220 B (JPN. TKKYO KOHO) Nov. 25, 1966 Caplus-RN; 14521-72-3p abstract.
Doherty Elizabeth M.
Fotsch Christopher H.
Han Nianhe
Hungate Randall W.
Liu Qingyian
Amgen Inc.
Chang Celia
Person Richard V.
LandOfFree
Vanilloid receptor ligands and their use in treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vanilloid receptor ligands and their use in treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vanilloid receptor ligands and their use in treatments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3727664